Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Apx001
2. 2091769-17-2
3. Fosmanogepix [inn]
4. Fosmanogepix [usan]
5. Apx-001
6. 1xq871489p
7. E1211
8. (2-amino-3-(3-(4-((pyridin-2-yloxy)methyl)benzyl)isoxazol-5-yl)pyridin-1-ium-1-yl)methyl Hydrogen Phosphate
9. Pyridinium, 2-amino-1-((phosphonooxy)methyl)-3-(3-((4-((2-pyridinyloxy)methyl)phenyl)methyl)-5-isoxazolyl)-, Inner Salt
10. Fosmanogepix (usan/inn)
11. Chembl4297591
12. Schembl22749842
13. Unii-1xq871489p
14. Ex-a5184
15. Who 10818
16. Db15183
17. 1169701-00-1
18. D11694
19. (12-amino-6-oxa-1(3),7(2)-dipyridina-2(5,3)-(1,2)oxazola- 4(1,4)-benzenaheptaphan-11-ium-11-yl)methyl Hydrogen Phosphate
20. (12-amino-6-oxa-1(3),7(2)-dipyridina-2(5,3)-(1,2)oxazola-4(1,4)-benzenaheptaphan-11-ium-11-yl)methyl Hydrogen Phosphate
21. (2-amino-3-(3-((4-(2-pyridyloxymethyl)phenyl)methyl)isoxazol-5-yl)pyridin-1-ium-1-yl)methyl Hydrogen Phosphate
22. [2-amino-3-[3-[[4-(pyridin-2-yloxymethyl)phenyl]methyl]-1,2-oxazol-5-yl]pyridin-1-ium-1-yl]methyl Hydrogen Phosphate
| Molecular Weight | 468.4 g/mol |
|---|---|
| Molecular Formula | C22H21N4O6P |
| XLogP3 | 1.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 9 |
| Exact Mass | 468.11987140 g/mol |
| Monoisotopic Mass | 468.11987140 g/mol |
| Topological Polar Surface Area | 148 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 644 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
PF-07842805 (fosmanogepix), a potential first-in-class, clinical-stage broad-spectrum antifungal treatment candidate for Candidemia, including Candida auris, and invasive mold infections.
Lead Product(s): Fosmanogepix
Therapeutic Area: Infections and Infectious Diseases Brand Name: PF-07842805
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2024
Lead Product(s) : Fosmanogepix
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Basilea Initiates Phase 3 Study with Antifungal Fosmanogepix for Candidemia
Details : PF-07842805 (fosmanogepix), a potential first-in-class, clinical-stage broad-spectrum antifungal treatment candidate for Candidemia, including Candida auris, and invasive mold infections.
Brand Name : PF-07842805
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 23, 2024
Details:
The funding aims to support the development of Basilea’s clinical stage first-in-class antifungal, APX-001 (fosmanogepix), which is being investigated for the treatment of invasive candidiasis.
Lead Product(s): Fosmanogepix
Therapeutic Area: Infections and Infectious Diseases Brand Name: APX-001
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: BARDA
Deal Size: $29.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 19, 2024
Lead Product(s) : Fosmanogepix
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : BARDA
Deal Size : $29.0 million
Deal Type : Funding
Basilea Partners with BARDA To Develop Novel Antifungals, Gets Initial Funding
Details : The funding aims to support the development of Basilea’s clinical stage first-in-class antifungal, APX-001 (fosmanogepix), which is being investigated for the treatment of invasive candidiasis.
Brand Name : APX-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 19, 2024
Details:
Basilea has acquired the rights to PF-07842805 (fosmanogepix), a potential first-in-class, clinical-stage broad-spectrum antifungal treatment candidate for the treatment of Candidemia, including Candida auris, and invasive mold infections.
Lead Product(s): Fosmanogepix
Therapeutic Area: Infections and Infectious Diseases Brand Name: PF-07842805
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Basilea Pharmaceutica
Deal Size: $147.0 million Upfront Cash: $37.0 million
Deal Type: Acquisition November 13, 2023
Lead Product(s) : Fosmanogepix
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Basilea Pharmaceutica
Deal Size : $147.0 million
Deal Type : Acquisition
Basilea Announces Acquisition of Fosmanogepix, a Phase-3-Ready Broad-Spectrum Antifungal
Details : Basilea has acquired the rights to PF-07842805 (fosmanogepix), a potential first-in-class, clinical-stage broad-spectrum antifungal treatment candidate for the treatment of Candidemia, including Candida auris, and invasive mold infections.
Brand Name : PF-07842805
Molecule Type : Small molecule
Upfront Cash : $37.0 million
November 13, 2023
Details:
With this acquisition Pfizer adds Amplyx’s lead compound, Fosmanogepix (APX001) to its pipeline and in addition to this Pfizer has secured ownership of Amplyx's early-stage pipeline that includes potential antiviral (MAU868) and antifungal (APX2039) therapies.
Lead Product(s): Fosmanogepix
Therapeutic Area: Infections and Infectious Diseases Brand Name: APX001
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 28, 2021
Lead Product(s) : Fosmanogepix
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Acquisition
Pfizer Acquires Amplyx Pharmaceuticals
Details : With this acquisition Pfizer adds Amplyx’s lead compound, Fosmanogepix (APX001) to its pipeline and in addition to this Pfizer has secured ownership of Amplyx's early-stage pipeline that includes potential antiviral (MAU868) and antifungal (APX2039) th...
Brand Name : APX001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 28, 2021
Details:
At IDWeek 2020, positive data from the Phase 2 clinical trial evaluating fosmanogepix, a novel IV and oral Gwt1 inhibitor, in patients with candidemia will be presented during an oral session at the American Society of Nephrology (ASN) Kidney Week 2020.
Lead Product(s): Fosmanogepix
Therapeutic Area: Infections and Infectious Diseases Brand Name: APX001
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
Lead Product(s) : Fosmanogepix
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : At IDWeek 2020, positive data from the Phase 2 clinical trial evaluating fosmanogepix, a novel IV and oral Gwt1 inhibitor, in patients with candidemia will be presented during an oral session at the American Society of Nephrology (ASN) Kidney Week 2020.
Brand Name : APX001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 16, 2020
Details:
Topline data from the study indicated fosmanogepix's success rate of 80 percent, meeting the primary endpoint and paving the way to a pivotal trial ahead.
Lead Product(s): Fosmanogepix
Therapeutic Area: Infections and Infectious Diseases Brand Name: APX001
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Lead Product(s) : Fosmanogepix
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Amplyx Touts Upbeat Readout from a Small PhII Study for Lead Antifungal
Details : Topline data from the study indicated fosmanogepix's success rate of 80 percent, meeting the primary endpoint and paving the way to a pivotal trial ahead.
Brand Name : APX001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 20, 2020
Details:
Amplyx plans to use this Series C funds to advance the clinical development of the company’s two product candidates, fosmanogepix (APX001) and MAU868 for the treatment of life-threatening fungal infections and BK Virus.
Lead Product(s): Fosmanogepix
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Pfizer Inc
Deal Size: $53.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 19, 2020
Lead Product(s) : Fosmanogepix
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : $53.0 million
Deal Type : Series C Financing
Details : Amplyx plans to use this Series C funds to advance the clinical development of the company’s two product candidates, fosmanogepix (APX001) and MAU868 for the treatment of life-threatening fungal infections and BK Virus.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 19, 2020
Details:
Amplyx has advanced development of its lead program, fosmanogepix (APX001). Enrollment has been completed in a Phase 2 trial evaluating the safety and efficacy of fosmanogepix for the treatment of infections caused by Candida.
Lead Product(s): Fosmanogepix
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2020
Lead Product(s) : Fosmanogepix
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix
Details : Amplyx has advanced development of its lead program, fosmanogepix (APX001). Enrollment has been completed in a Phase 2 trial evaluating the safety and efficacy of fosmanogepix for the treatment of infections caused by Candida.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
